This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

ASCO '12 Stocks: Winners and Losers

Stocks in this article: DNDN MDVN ONXX IMGN AVEO CLDX SNTA RHHBY BMY AEZS

CHICAGO ( TheStreet) -- Snap biotech and drug stock judgments after a weekend spent at the American Society of Clinical Oncology (ASCO) annual meeting:

Bristol-Myers Squibb's (BMY) anti-PD-1 immunotherapy generated the most ASCO buzz and has blockbuster potential across several solid tumors.

Yes, Johnson & Johnson (JNJ) created a bio-statistical mess by stopping the Zytiga "pre-chemo" prostate cancer trial too soon, before a statistically significant survival benefit could be demonstrated. No, it won't stop FDA from approving.

Medivation (MDVN - Get Report) and its prostate cancer drug MDV3100 emerge from the ASCO weekend stronger, not from any significant new clinical data, but because the company can capitalize on J&J's stumbles.

Dendreon (DNDN) loses. Provenge has formidable competition in the "pre-chemo" prostate cancer treatment market. The only thing positive for Dendreon this weekend was that investors expected ASCO to be bad for the struggling company. But if Provenge sales stall through the end of the year, the stock can go lower.

Onyx Pharmaceuticals (ONXX): Good and bad. Carfilzomib is a real multiple myeloma drug but investor sentiment remains pessimistic about the outcome of the upcoming June 20 FDA advisory panel meeting. Key question: Is a 15% response rate in dual refractory -- Revlimid and Velcade -- patients strong enough? A silver lining: Any significant dip in Onyx's stock price is likely to be bought.

Roche (RHHBY): T-DM1 in breast cancer was the star of Sunday's plenary session, a blockbuster in the making. Remember when FDA issued a refuse-to-file letter on T-DM1 in August 2010, refusing to even review the drug? That decision was stupid then and looks even lamer today.

Unfortunately, ImmunoGen (SYMBOL) hasn't invented a wayback machine to allow the company to re-negotiate its mid-single digit royalty rate on T-DM1 sales. ImmunoGen's valuation today already bakes in multi-billion dollar T-DM1 sales. That's the hard truth.

Celldex Therapeutics (CLDX): Remember, CDX-011 is an antibody-drug conjugate, just like T-DM1.

Aveo Pharmaceuticals (AVEO - Get Report): A "patient preference" study pitting Tivozanib against Pfizer's Sutent will be started this year. Smart move. The kidney cancer drug market is crowded and competitive so more data convincing doctors to use tivozanib before Sutent (or even Glaxo's Votrient) should help.

Synta Pharmaceuticals (SNTA): An A-list of healthcare hedge funds attended the company's Saturday night cocktail party, with anticipation thick for the release of interim results from the phase II study of the lung cancer drug ganetespib later this month. Synta CEO Safi Bahcall has been hinting at boffo results and of interest from big-name partners. He needs to deliver this time to erase the memory of Synta's failed skin cancer drug.

Aeterna Zentaris (AEZS) had no presence at ASCO this year but loses nonetheless because it continues to waste shareholder money on perifosine, a drug that raised the risk of dying in a phase III colon cancer trial.

--Written by Adam Feuerstein in Chicago.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs